Theravance Biopharma Announces New Employment Inducement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Theravance Biopharma Announces New Employment Inducement Awards

DUBLIN, IRELAND--(Marketwired - Nov 3, 2015) - Theravance Biopharma, Inc. ( NASDAQ : TBPH ) ("Theravance Biopharma" or the "Company") announced today that stock options to purchase an aggregate of 39,500 of the Company's ordinary shares were granted to four new non-executive officer employees on November 2, 2015. The options were granted in accordance with NASDAQ Listing Rule 5635(c)(4) under the Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan (the "Inducement Plan"), which the Board of Directors of Theravance Biopharma adopted in October 2014 to facilitate the granting of equity awards to new employees. Each option has an exercise price per share equal to $16.08, which was the closing price of one Theravance Biopharma ordinary share on the Nasdaq Global Market on the date of grant. The options vest over four years, with 25% of the option shares vesting on the first anniversary of the date of grant and the remaining 75% of the option shares vesting in monthly installments over the three years thereafter. The options have a ten year term, and are subject to the terms and conditions of the Inducement Plan and applicable stock option agreement.

About Theravance Biopharma

The mission of Theravance Biopharma ( NASDAQ : TBPH ) is to create value from a unique and diverse set of assets: an approved product; a development pipeline of late-stage assets; and a productive research platform designed for long-term growth.

Our pipeline of internally discovered product candidates includes potential best-in-class opportunities in underserved markets in the acute care setting, representing multiple opportunities for value creation. VIBATIV ® (telavancin), our first commercial product, is a once-daily dual-mechanism antibiotic approved in the U.S., Europe and certain other countries for certain difficult-to-treat infections. Revenfenacin (TD-4208) is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily, nebulized treatment for COPD. Axelopran (TD-1211) is an investigational potential once-daily, oral treatment for opioid-induced constipation (OIC). Our earlier-stage clinical assets represent novel approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease. In addition, we have an economic interest in future payments that may be made by GlaxoSmithKline plc pursuant to its agreements with Theravance, Inc. relating to certain drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol (or "Closed Triple").

With our successful drug discovery and development track record, commercial infrastructure, experienced management team and efficient corporate structure, we believe that we are well positioned to create value for our shareholders and make a difference in the lives of patients.

For more information, please visit www.theravance.com .

THERAVANCE ® , the Cross/Star logo, MEDICINES THAT MAKE A DIFFERENCE ® and VIBATIV ® are registered trademarks of the Theravance Biopharma group of companies.

Contact Information: Renee Gala Chief Financial Officer 650-808-4045 investor.relations@theravance.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 173

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 123

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 203

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

dbt Labs Transforms Data Management with MetricFlow Open Source

Updated Category News Views 735

Embracing Open Source with MetricFlow In a groundbreaking move, dbt Labs recently announced its commitment to advancing trustworthy AI by open sourcing MetricFlow. This initiative represents a significant turning point in how organizations manage and utilize data in the era of artificial intelligence. The shift to an Apache 2.0 license not only safeguards the integrity of...

Continue Reading
EssilorLuxottica Achieves Euro 2 Billion Bond Issuance Success

Updated Category News Views 117

EssilorLuxottica's Successful Bond Issuance EssilorLuxottica has reached a noteworthy milestone by successfully issuing a Euro 2 billion bond at an attractive average rate of 2.99%. This strategic financial move highlights the company's strong position in the market and its appeal to investors. Details of the Bond Issuance The bond issuance features tenors of 4.5 years...

Continue Reading
Streamlined Home Selling Solutions Introduced in North Carolina

Updated Category News Views 292

Revolutionizing Home Selling in North Carolina Fair Cash Offers For Homes has recently launched its innovative service, ‘Sell Your House Fast North Carolina,’ designed to facilitate quick and efficient sales for homeowners. With the ever-changing real estate landscape, many individuals find themselves needing to sell their properties under various circumstances,...

Continue Reading
Ipsen Employee Admits to Insider Trading on Cancer Drug Deal

Updated Category News Views 268

Guilty Plea Tied to a Drugmaker’s Takeover Plans An employee at the French pharmaceutical company Ipsen has agreed to plead guilty to insider trading. The case, centered on trading ahead of a proposed acquisition, underscores the stakes around confidentiality in drug development and the pressures that test corporate governance. What Prosecutors Allege Dishant Gupta,...

Continue Reading
Oscar Health Achieves 52-Week Record with $23.45 Stock Price

Updated Category News Views 221

Oscar Health Achieves New Stock Performance Highs In a striking example of market resilience, Oscar Health, Inc. (OSCR) has reached an impressive 52-week high with its stock hitting $23.45. This achievement signifies a remarkable growth phase for the company, which has experienced an incredible one-year change of 288.51%. Investors have shown strong support for Oscar...

Continue Reading